Core Viewpoint - Mindray Medical announced a cash dividend distribution plan for its shareholders, indicating a commitment to returning value to investors through a significant payout [1] Group 1: Dividend Announcement - The company will distribute a cash dividend of 13.5 RMB per 10 shares to all shareholders, which includes tax [1] - The record date for the dividend is set for November 11, 2025, and the ex-dividend date is November 12, 2025 [1]

Investment Rating - The investment rating for the company is "Buy" [6] Core Insights - The company reported a revenue of 25.8 billion yuan for the first three quarters of 2025, a year-on-year decline of 12%, but Q3 revenue showed a positive growth of 1.5% year-on-year [1] - The net profit attributable to the parent company for the first three quarters was 7.6 billion yuan, down 29% year-on-year, with Q3 net profit at 2.5 billion yuan, a decline of 19% year-on-year [1] - The company’s overseas revenue in Q3 grew by 12% year-on-year, indicating an accelerating trend [1] Revenue Growth - The international business saw a 12% year-on-year growth in Q3, with Europe performing particularly well, exceeding 20% growth [2] - The minimally invasive surgery segment experienced over 25% growth, while the international life information and support line achieved double-digit growth [3] - The in-vitro diagnostics segment saw a 2.81% decline in Q3 revenue, but international sales in this segment grew by double digits [3] Profitability Analysis - The gross margin for the first three quarters of 2025 was 62.0%, a decrease of 2.9 percentage points year-on-year, while Q3 gross margin improved to 62.5%, up 0.79 percentage points year-on-year [4] - The net profit margin for 2025 was 30.2%, down 6.1 percentage points year-on-year, with Q3 net profit margin at 28.4%, down 6.5 percentage points year-on-year [4] Financial Forecast and Valuation - Revenue projections for 2025-2027 are 35.728 billion, 38.171 billion, and 42.879 billion yuan, with year-on-year growth rates of -2.72%, 6.84%, and 12.33% respectively [5] - The net profit attributable to the parent company is forecasted to be 10.563 billion, 11.760 billion, and 13.615 billion yuan for the same period, with corresponding year-on-year growth rates of -9.48%, 11.34%, and 15.77% [5] - The estimated EPS for 2025-2027 is 8.71, 9.70, and 11.23 yuan, with a PE ratio of 21 times for 2026 [5]

Core Viewpoint - The overall performance of A-share medical device companies has become clearer as of the end of Q3 2025, with the industry facing continued pressure but showing signs of recovery in the third quarter [1][2]. Financial Performance - As of now, 131 medical device companies have released their Q3 2025 financial data, with total revenue of 179.21 billion yuan, a year-on-year decrease of 2.24%, and a net profit attributable to shareholders of 26.73 billion yuan, down 13.93% year-on-year [2]. - In Q3 2025, the medical device sector saw a revenue increase to 60.39 billion yuan, a year-on-year growth of 2.05%, while net profit decreased by 5.07%, showing a narrowing decline compared to Q2 [2]. - Among the companies, only Mindray Medical achieved over 25.83 billion yuan in revenue for the first nine months, while 50 companies reported net profits exceeding 1 billion yuan [3]. Segment Performance - The performance of different segments within the medical device industry remains divergent, with high-value consumables like orthopedics and electrophysiology showing positive growth due to factors such as technological innovation and international expansion [3][4]. - For instance, Sanyou Medical reported a staggering net profit growth of 623.19% year-on-year, driven by strong sales of its core product, the ultrasonic bone knife [4]. Medical Equipment Sector - The medical equipment sector is experiencing a recovery, with companies like United Imaging achieving a revenue of 8.86 billion yuan in the first three quarters, a year-on-year increase of 27.39% [5]. - Other companies, such as Ribo Instrument, also reported significant growth, with a net profit increase of 118% in Q3 [5][6]. In Vitro Diagnostics (IVD) Sector - The IVD sector continues to face challenges, with only 9 out of 39 companies reporting revenue growth in the first three quarters [7]. - Major players like Mindray Medical and Antu Bio reported declines in revenue, with Mindray's IVD product line experiencing a 2.81% drop in Q3 [8][9]. - New Industries is the only company among the "Five Tigers" to report revenue growth, although its net profit decreased by 12.92% year-on-year [8]. Market Outlook - Despite the current challenges, industry experts believe that the market is beginning to show positive signs, with the most difficult period likely behind [9]. - Companies with core technological advantages and strong international presence are expected to recover more quickly as the market stabilizes [9].

证券代码：300760 证券简称：迈瑞医疗 公告编号：2025-049 深圳迈瑞生物医疗电子股份有限公司 2025年第三次中期权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（下称"本公司"或"公司"）2025年第三次中期 权益分派方案已获2025年10月28日召开的第八届董事会第十五次会议审议通过，在公司 2024年年度股东大会决议授权范围内，无需再次提交股东会审议。现将权益分派事宜公告 如下： 一、股东会及董事会审议通过利润分配方案等情况 1、公司于2025年5月20日召开2024年年度股东大会，审议通过了《关于2024年度、2025 年第一次中期利润分配预案及提请股东大会授权董事会制定2025年其他中期分红方案的议 案》，同意授权董事会根据股东大会决议在符合利润分配的条件下制定其他具体的2025年中 期分红方案。公司于2025年10月28日召开第八届董事会第十五次会议，审议通过了《关于 2025年第三次中期利润分配方案的议案》，2025年第三次中期利润分配方案为：以公司2025 年9月30日的总股本1,2 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][4]. Core Views - The pharmaceutical sector has shown stronger performance compared to the overall market, with a 1.31% increase in the biotechnology sector, while the overall A-share market rose by 0.27% [27]. - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector is 38.80x, which is at the 81.52 percentile of the historical valuation over the past five years [27][32]. Summary by Sections Market Performance - In the past week, the chemical pharmaceutical sector led the gains with a 3.07% increase, while the medical device sector saw a decline of 1.15% [27]. - The report highlights that the largest sub-sectors by holding proportion are chemical preparations and other biological products, with significant increases in holdings for other biological products and CXO [17][11]. Fund Holdings Analysis - The total scale of pharmaceutical funds reached 311.8 billion, a slight decrease of 0.2% from the previous quarter [11]. - The proportion of pharmaceutical holdings in all funds is 9.68%, with a decrease of 0.09 percentage points [14]. - The top three pharmaceutical stocks by the number of funds holding them are 恒瑞医药 (734 funds), 药明康德 (564 funds), and 信达生物 (297 funds) [22]. Valuation and Recommendations - The report recommends several companies, including: - 迈瑞医疗, noted for its strong R&D and sales capabilities, benefiting from domestic medical infrastructure and product upgrades [36]. - 药明康德, recognized for its comprehensive new drug development service platform [36]. - 爱尔眼科, the largest eye care institution in China, focusing on high-quality medical services [36]. - 新产业, a leader in the field of chemiluminescence immunoassay [36]. - The report also provides earnings forecasts for key companies, indicating a positive outlook for their profitability in the coming years [4].

Core Insights - The increase in operating expenses for the third quarter is attributed to the company's intensified investment in international business, leading to a faster growth rate in this segment [2] - The company has been steadily increasing the number of employees in international marketing and services over the past few years, with a significant rise in local staff in developing countries to enhance the overseas localization platform [2] Summary by Categories - **Operating Expenses** - The company reported an increase in sales expenses for the third quarter due to heightened investments in international operations [2] - **International Business Growth** - The growth in international business has accelerated in the third quarter, supported by the increased workforce dedicated to this area [2] - **Employee Expansion** - There has been a notable increase in the number of local employees in developing countries, which is part of the strategy to build a robust overseas localization platform [2]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, particularly recommending a focus on innovative drugs and sectors with improving performance such as medical devices and CXO [1][10]. Core Insights - The pharmaceutical sector in Q3 2025 showed signs of recovery with a year-on-year revenue growth of 0.6% in Q3, marking the first positive growth in four quarters [1][10]. - Innovative drugs demonstrated a remarkable revenue growth of 36% in Q3 2025, with a turnaround in net profit from a loss of 500 million to a profit of 1.5 billion [10]. - The CXO sector also showed strong performance with a revenue growth of 10.9% and a net profit increase of 47.7% year-on-year, indicating a trend reversal [10]. Summary by Sections Q3 2025 Performance - The A-share pharmaceutical sector, excluding certain companies, achieved total revenue of 1,806.4 billion with a year-on-year decline of 1.9% and a net profit of 139.2 billion, down 5.1% year-on-year [2][11]. - In Q3 2025, total revenue reached 600.4 billion, reflecting a year-on-year increase of 0.6% but a quarter-on-quarter decrease of 0.4% [2][11]. Profitability and Margins - The gross profit for the pharmaceutical sector in Q3 2025 was 189.1 billion, with a gross margin of 31.5%, slightly down from the previous year [5][8]. - The overall net profit margin for Q3 2025 was 6.8%, showing a slight decline compared to the previous year [8]. Cash Flow - The sector reported a net cash inflow from operating activities of 59.1 billion in Q3 2025, representing a year-on-year growth of 17.9% [7][13]. Subsector Performance - The innovative drug sector's revenue growth of 36% and the CXO sector's revenue growth of 10.9% highlight the strong recovery and growth potential within these subsectors [10][11]. - The report emphasizes the importance of focusing on companies such as 恒瑞医药, 长春高新, and 药明康德, which are expected to perform well in the current market environment [1][10].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, indicating a positive outlook for the sector compared to the overall market performance [22]. Core Insights - The pharmaceutical sector has shown signs of recovery, with the first positive year-on-year revenue growth in four quarters, driven by strong performances in the innovative drug and CXO segments [2][11]. - Innovative drugs achieved a remarkable 36% revenue growth in Q3 2025, transitioning from a loss of 500 million to a profit of 1.5 billion, highlighting the sector's high growth potential [11]. - The CXO segment has also shown a significant turnaround, with a year-on-year revenue growth of 10.9% and a net profit increase of 47.7%, expected to maintain mid-to-high growth in the coming year [11]. Summary by Sections Industry Performance - In the first three quarters of 2025, the A-share pharmaceutical and biotechnology sector, excluding certain companies, generated total revenue of 1,806.4 billion yuan, a year-on-year decrease of 1.9%, and a net profit of 139.2 billion yuan, down 5.1% [2][3]. - For Q3 2025, total revenue reached 600.4 billion yuan, reflecting a year-on-year increase of 0.6% but a quarter-on-quarter decrease of 0.4% [2][3]. Profitability Metrics - The gross profit for Q3 2025 was 189.1 billion yuan, with a gross margin of 31.5%, showing a slight decline compared to previous periods [5][8]. - The overall net profit margin for the sector in Q3 2025 was 6.8%, down 0.05 percentage points year-on-year and 1.47 percentage points quarter-on-quarter [8]. Cash Flow Analysis - The sector reported a net cash inflow from operating activities of 59.1 billion yuan in Q3 2025, marking a year-on-year increase of 17.9% and achieving positive growth for two consecutive quarters [7][14]. Subsector Performance - The report highlights the strong performance of the innovative drug and CXO subsectors, with innovative drugs showing a significant recovery and CXO experiencing a positive trend reversal [11][12].

Investment Rating - The report maintains an "Overweight" rating for the medical device sector [6] Core Insights - The medical device sector is entering a turning point, driven by innovation and international expansion as key growth drivers [12][29] - The overall revenue for medical device companies in the first three quarters of 2025 was 183.45 billion yuan, a year-on-year decrease of 3.90%, while the net profit excluding non-recurring items was 22.70 billion yuan, down 17.70% [8][15] - Different sub-sectors show significant divergence in performance, with high-value consumables showing a growth of 5.12%, while in vitro diagnostics faced a decline of 13.94% [8][15] Summary by Sections Medical Device Sector Overview - The medical device sector is experiencing a recovery with improved bidding processes and a gradual clearing of high-cost consumables [8][15] - The revenue growth rate for the medical device sector in Q3 2025 was 9.99%, with a net profit growth of 4.87% [9][16] High-Value Consumables - High-value consumables saw a revenue increase of 5.12% in the first three quarters of 2025, with a net profit growth of 1.18% [29] - The sector is stabilizing as it enters the post-collection phase, with significant growth driven by innovation and international expansion [29] Medical Equipment - The medical equipment sector's revenue decreased by 1.02% in the first three quarters of 2025, but showed a positive trend in Q3 with a revenue increase of 9.99% [9][16] - The sector is expected to experience structural differentiation in demand as bidding processes improve [9] Low-Value Consumables - Low-value consumables experienced a revenue decline of 0.75% in the first three quarters of 2025, with a significant drop in net profit by 21.68% [9][16] - The sector's performance is heavily influenced by international market conditions, but there is potential for recovery in Q4 2025 [9] In Vitro Diagnostics - The in vitro diagnostics sector faced a revenue decline of 13.94% in the first three quarters of 2025, with net profit down 32.20% [9][16] - The sector is expected to stabilize by the end of 2025 as negative impacts from policies begin to clear [9]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% against the benchmark index within the next 6 to 12 months [4][17]. Core Views - The company has shown signs of a performance turnaround, with quarterly improvements in its fundamental performance driven by accelerated overseas growth [1][6]. - The company reported a revenue of 25.834 billion yuan for the first three quarters of 2025, a year-on-year decrease of 12.38%, while the net profit attributable to the parent company was 7.570 billion yuan, down 28.83% [6]. - The third quarter of 2025 saw a revenue of 9.091 billion yuan, marking a year-on-year growth of 1.53%, indicating a potential inflection point in performance [6]. Summary by Sections Financial Performance - For 2023A, the company is projected to achieve a revenue of 34.932 billion yuan, with a year-on-year growth rate of 15.0%. However, a decline of 1.9% is expected in 2025E [4]. - The net profit attributable to the parent company is forecasted to be 11.582 billion yuan in 2023A, with a growth rate of 20.6%, but a significant drop of 14.6% is anticipated in 2025E [4]. - The company’s gross margin for the first three quarters of 2025 was 61.95%, down 2.92 percentage points year-on-year, primarily due to pricing pressures in the domestic market [6]. Business Segments - The in-vitro diagnostics business continues to perform strongly overseas, with international revenue accounting for 37% of the segment's total in the first three quarters of 2025 [6]. - The life information and support business returned to growth in Q3 2025, with a revenue increase of 2.60%, driven by a more than 25% growth in minimally invasive surgery [6]. - The medical imaging business maintained its market position, with a revenue of 1.689 billion yuan in Q3 2025, showing a significant reduction in the decline compared to the first half of the year [6]. Future Outlook - The company expects revenue growth to accelerate in Q4 2025, with projected revenues of 36.011 billion yuan for 2025E, followed by 39.956 billion yuan in 2026E and 44.404 billion yuan in 2027E [4][6]. - The forecasted net profit for 2025E is 9.962 billion yuan, with a recovery expected in subsequent years, reaching 12.562 billion yuan by 2027E [4][6].